Shenzhen Chipscreen Biosciences and Chengdu Chipscreen Pharmaceutical have presented new ATR kinase inhibitors reported to be useful for the treatment of cancer.

Shanghai Shengdi Pharmaceutical, Shanghai Senhui Pharmaceutical and Jiangsu Hengrun Pharmaceutical have divulged new cephems (cephalosporins) reported to be useful for the treatment of Gram-negative bacterial infections.

AbbVie has patented cystic fibrosis transmembrane conductance regulator (CFTR) (deltaF508 mutant) correctors reported to be useful for the treatment of cystic fibrosis.

Thryv Therapeutics has presented new pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives acting as serum/glucocorticoid-regulated kinase 1 (SGK1) inhibitors reported to be useful for the treatment of cancer, cardiovascular disorders, Lafora disease and Parkinson's disease.

Immatics Biotechnologies has divulged immunogenic peptides claimed to be potentially useful as vaccines for the prevention and treatment of cancer.

Pfizer has patented isolated engineered immune cells expressing chimeric antigen receptors (CARs) comprising an epidermal growth factor receptor variant 3 (EGFRvIII) binding domain, a transmembrane domain and an intracellular signaling domain claimed to be potentially useful for the treatment of cancer.

Servier and Vernalis Group have divulged new spirocyclohexane derivatives acting as induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors and apoptosis inducers reported to be useful for the treatment of cancer, immunological disorders and autoimmune diseases.

Helios-Huaming BioPharma has synthesized new substituted salicylamide compounds acting as protein-arginine deiminase type-4 (PADI4) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis and ischemia-reperfusion injury, among other disorders.

Yale University has presented new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection.

Shanghai Hengrui Pharmaceutical and Jiangsu Hengrui Medicine have described cyclohexadiimide derivatives reported to be useful for the treatment of cancer and neurological disorders.